Seacross Pharmaceuticals Limited

Huiyu Pharma (known as Seacross Pharma in UK) Founded in 2010 with 13 years industry history, and Listed on Shanghai Stock Exchange since 2017; Rapidly expanding wordwide with subsidiaries in Germany, USA,UK, Ireland etc.; (1600 emplyees); Marketing in over 100 countries and 300 MAs obtained; EU/FDA certified factories, with 10 injection production workshops and 3 fully automated packaging workshops; Newly built R&D center mainly Focusing on the three major areas of small molecule innovative drugs, biological innovative drugs and high-quality generic drugs, By 2023, Huiyu has more than 100 research projects, Including 12 innovative anti-tumor drugs, 7 small molecule innovative drug new product development projects; 5 new product development projects for bio-innovative drugs, 2 projects of 505B2; And high-quality generic drugs (including API and excipients);